Jefferies Financial Group Lowers Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target to $8.00

Key Points

• Jefferies cut Eyepoint Pharmaceuticals’ price target from $30 to $8 but maintained a “buy” rating, implying about 72.6% upside from the stock’s $4.63 price.
• EYPT shares fell $10.12 during Monday trading, while the company reported a quarterly loss of $1.09 per share, missing estimates by $0.08.
• Despite mixed analyst opinions, the stock has a consensus “Moderate Buy” rating and an average price target of $40.33; institutional investors and hedge funds own 99.41% of shares.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) had its price objective lowered by equities researchers at Jefferies Financial Group from $30.00 to $8.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Jefferies Financial Group's price target would suggest a potential upside of 72.60% from the stock's current price.

Several other research firms have also recently commented on EYPT. Royal Bank Of Canada reduced their target price on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an "outperform" rating for the company in a research note on Thursday, May 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Eyepoint Pharmaceuticals in a report on Friday, July 17th. Cantor Fitzgerald downgraded shares of Eyepoint Pharmaceuticals from an "overweight" rating to a "neutral" rating in a research note on Monday. Stifel Nicolaus assumed coverage on shares of Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They set a "buy" rating and a $40.00 price objective for the company. Finally, Chardan Capital reissued a "buy" rating and issued a $65.00 target price on shares of Eyepoint Pharmaceuticals in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $40.33.

Eyepoint Pharmaceuticals Stock Performance

Shares of NASDAQ EYPT traded down $10.12 during midday trading on Monday, reaching $4.63. 34,567,836 shares of the company's stock were exchanged, compared to its average volume of 1,510,330. Eyepoint Pharmaceuticals has a 52-week low of $3.95 and a 52-week high of $19.11. The business's fifty day moving average price is $13.23 and its two-hundred day moving average price is $13.70. The stock has a market capitalization of $399.58 million, a PE ratio of -1.22 and a beta of 1.76.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The business had revenue of $0.51 million during the quarter, compared to analysts' expectations of $0.45 million. Analysts predict that Eyepoint Pharmaceuticals will post -3.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System raised its stake in Eyepoint Pharmaceuticals by 2,158.3% during the first quarter. California State Teachers Retirement System now owns 105,101 shares of the company's stock worth $1,355,000 after acquiring an additional 100,447 shares during the period. Commodore Capital LP bought a new position in Eyepoint Pharmaceuticals during the 1st quarter worth $36,414,000. Simplify Asset Management Inc. increased its position in Eyepoint Pharmaceuticals by 314.9% in the fourth quarter. Simplify Asset Management Inc. now owns 375,264 shares of the company's stock worth $6,856,000 after buying an additional 284,824 shares during the period. Walleye Capital LLC acquired a new stake in Eyepoint Pharmaceuticals in the first quarter worth $3,869,000. Finally, Vanguard Group Inc. lifted its stake in Eyepoint Pharmaceuticals by 27.1% in the fourth quarter. Vanguard Group Inc. now owns 4,822,139 shares of the company's stock valued at $88,100,000 after buying an additional 1,027,623 shares during the last quarter. 99.41% of the stock is owned by institutional investors and hedge funds.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source